Aim. Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods. This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient’s serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software. Results. The mean age of subjects in breast cancer and control groups was and years, respectively. The serum miR-155 expression was higher in the cancer group () compared to the control group (). There was a significant relationship between serum miR-155 expression and the tumor grade (), tumor stage (), and tumor size () of the patients. However, no relationship between miR-155 expression and the presence of lymph node involvement (), HER2 (), Ki-67 (), progesterone receptor (), and estrogen receptors () was found. The ROC curve analysis showed that the AUC was 0.89 (77.78% sensitivity and 88.89% specificity), and the cutoff was 1.4 (Youden index: 0.6667) for detecting breast cancer. Conclusion. The findings of this study revealed that serum miR-155 may serve as a potential noninvasive molecular biomarker for breast cancer diagnosis and can help predict the grade of the disease.

中文翻译：

---

MicroRNA-155在乳腺癌中诊断作用的临床评价。

瞄准。包括 microRNAs (miRs) 在内的生化标志物可能有助于乳腺癌的诊断和预后。本研究旨在评估乳腺癌患者的血清 miR-155 表达和受体。方法。这项病例对照研究对 36 名乳腺癌患者和 36 名健康个体进行。从患者血清中提取 RNA 后，合成 cDNA。使用 RT-qPCR 测量 miR-155 的表达。从患者文件中提取人口统计学和组织化学数据。使用社会科学统计软件包（SPSS）软件分析数据。结果。乳腺癌和对照组受试者的平均年龄为和年，分别。癌症组血清 miR-155 表达较高（)与对照组 (）。血清 miR-155 表达与肿瘤分级有显着相关性（),肿瘤分期 ()和肿瘤大小 ()的患者。然而，miR-155 表达与淋巴结受累之间没有关系（), HER2 (), Ki-67 (),孕激素受体 ()和雌激素受体 ()被发现。ROC曲线分析显示，检测乳腺癌的AUC为0.89（敏感性77.78%，特异性88.89%），临界值为1.4（约登指数：0.6667）。结论。这项研究的结果表明，血清 miR-155 可作为乳腺癌诊断的潜在非侵入性分子生物标志物，并有助于预测疾病的分级。